Study details
Enrolling now
Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure
Jon Simmons
NCT IDNCT04445285ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
44
Study length
about 1.8 years
Ages
18+
Locations
1 site in AL
About this study
This trial is testing if giving a medication called rhDNase to people with COVID-19 who are having trouble breathing will make them safer and reduce the risk of dying within 28 days. The treatment involves nebulized Dornase Alpha (rhDNase).
Based on ClinicalTrials.gov records.
What participants do
- 1.Take 0.9%sodium chloride
- 2.Take Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase)
PhasePhase 2
Drug0.9%sodium chloride
Routeoral
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low5%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
sodium chloride
Drug routes
oral (Oral Tablet)
Body systems
Infectious